Meningococcal disease: History, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention

Indian Journal of Medical Microbiology

Volumn 24, Issue 1, 2006, Pages 7-19

  Manchanda, V ^a   Gupta, S ^b   Bhalla, P ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b NATIONAL INSTITUTE OF COMMUNICABLE DISEASES   (India)

Author keywords

Ciprofloxacin resistance; Delhi; India; Neisseria meningitidis; Outbreak; Polysaccharide vaccines

Indexed keywords

AMPICILLIN; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; LIPOOLIGOSACCHARIDE; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; MINOCYCLINE; OFLOXACIN; PENICILLIN G; POLYSACCHARIDE VACCINE; PORIN; RIFAMPICIN; SULFADIAZINE; TOLL LIKE RECEPTOR 4; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTHRITIS; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM PILUS; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CULTURE MEDIUM; DRUG EFFICACY; EPIDEMIC; EPIDEMIC MENINGITIS; FEVER; GRAM STAINING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MUCOSA; NASOPHARYNX; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NONHUMAN; OROPHARYNX; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; RASH; REVIEW; RISK ASSESSMENT; SEROTYPING; SHWARTZMAN PHENOMENON; SINGLE DRUG DOSE; SKIN BLEEDING;

EID: 33645517868     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.19888     Document Type: Review

References (102)

1. Vieusseux M. Mémoire sur la maladie qui a regné a Genêve au printemps de 1805. J Med Chir Pharmacol 1805;11:163.
2. Weichselbaum A. Ueber die Aetiologie der akuten Meningitis cerebrospinalis. Fortschr Med 1887;5:573-83.
3. Marchiafava E, Celli A. Spra i micrococchi della meningite cerebrospinale epidemica. Gazz degli Ospedali 1884;5:59.
4. Flexner S. The results of serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913;17:553-76.
5. Jochmann G. Versuche zur Serodiagnostik un Serotherapie der epidemischen Genickstarre. Dtsch Med Wochenschr 1906;1:788-93
6. Rosenstein NE, Perkins BA. Update on Haemophilus influenzae serotype b and meningococcal vaccines. Pediatr Clin North Am 2000;47:337-52.
7. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia:a review and recent experience. Pediatr Infect Dis J 1996:15:967-79.
8. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998:106:505-25.
9. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 1985;7:504-10.
10. Scholten RJ, Kuipers B, Valkenburg HA, Dankert J, Zollinger WD, Poolman JT. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol. 1994;41:236-43.
11. Mandrell RE, Zollinger WD. Lipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition. Infect Immun 1977;16:471-5.
12. Stephens DS, Whitney AM, Rothbard J, Schoolnik GK. Pili of Neisseria meningitidis. Analysis of structure and investigation of structural and antigenic relationships to gonococcal pili. J Exp Med 1985;161:1539-53.
13. Taha MK, Alonso JM, Cafferkey M, Caugant DA, Clarke SC, Diggle MA, et al. Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol 2005;43:144-9.
14. Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997:94:271-6.
15. Stephens DS. Uncloacking the meningococcus:dynamics of carriage and disease. Lancet 1999;353:941-2.
16. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998;95:3140-5.
17. Bjorvatn B, Hassan-King M, Greenwood B, Haimanot RT, Fekade D, Sperber G. DNA fingerprinting in the epidemiology of African serogroup A Neisseria meningitidis. Scand J Infect Dis 1992;24:323-32.
18. Achtman M. Global epidemiology of meningococcal disease. In: Meningococcal disease. Cartwright K, Editors. John Wiley & Sons Ltd: Chichester, United Kingdom; 1995. p. 159-75.
19. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989;2:S118-24.
20. World Health Organization Working Group. Control of epidemic meningococcal diseases: WHO practical guidelines. Lyon, France: Edition Foundation Marcel Merieux; 1995.
21. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180:1894-901.
22. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiol Infect 1999;122:41-9.
23. Band JD, Chamberland ME, Platt T, Weaver RE, Thornsberry C, Fraser DW. Trends in meningococcal disease in the United States, 1975-1980. J Infect Dis 1983;148:754-8.
24. Popovic T, Sacchi CT, Reeves MW, Whitney AM, Mayer LW, Noble CA, et al. Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis 2000;6:428-9.
25. Taha MK, Achtman M, Alonso JM, Greenwood B, Ramsay M, Fox A, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000;356:2159.
26. Riou JY, Djibo S, Sangare L, Lombart JP, Fagot P, Chippaux JP, et al. A predictable comeback:the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull World Health Organ 1996;74:181-7.
27. Vogel G. Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso. Science 2003;299:1499-501.
28. Fischer M, Perkins BA. Neisseria meningitidis serogroup B:emergence of the ET-5 complex. Semin Pediatr Infect Dis 1997;8:50-6.
29. Kertesz DA, Coulthart MB, Ryan JA, Johnson WM, Ashton FE. Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada. J Infect Dis 1998;177:1754-7.
30. Scholten RJ, Poolman JT, Valkenburg HA, Bijlmer HA, Dankert J, Caugant DA. Phenotypic and genotypic changes in a new clone complex of Neisseria meningitidis causing disease in The Netherlands, 1958-1990. J Infect Dis 1994;169:673-6.
31. Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet 1985;2:829-30.
32. Response to epidemic meningitis in Africa, 1997. Wkly Epidemiol Rec 1997;42:313-8.
33. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000;13:144-66.
34. http://w3.whosea.org/EN/Section10/Section 1973_9755.htm (WHO website) Accessed June 17, 2005.
35. CD alert. Monthly Newsletter of National Institute of Communicable Diseases. Directorate General of Health Services: Government of India; 2005;9:1-8.
36. Basu RN, Prasad R, Ichhpujani RL. Meningococcal meningitis in Delhi and Other areas. Commun Dis Bull 1985;2:1
37. Suri M, Kabra M, Singh S, Rattan A, Verma IC. Group B meningococcal meningitis in India. Scand J Infect Dis 1994;26:771-3.
38. Ayyagari A, Dubey ML, Bhandari SK. Sulphadiazine resistant strains of Neisseria meningitidis during an outbreak of meningococcal meningitis. Indian J Med Res 1987;85:249-52.
39. Ichhpujani RL, Mohan R, Grover SS, Joshi PR, Kumari S. Nasopharyngeal carriage of Neisseria meningitidis in general population and meningococcal disease. J Commun Dis 1990;22:264-8.
40. Paul VK, Bhujwala RA, Ghai OP, Shriniwas, Ahuja GK, Verma IC, et al. Nasopharyngeal carriers among contact of patients of Neisseria meningitidis infection in Delhi. Indian J Med Res 1987;86:429-32
41. Bhavsar BS, Saxena DM, Kantharia SL, Somasunderam C, Mehta NR. Meningococcal meningitis in an industrial area adjoining Surat City-some clinico-epidemiological aspects. J Commun Dis 1989;21:96-106.
42. Annapurna ME, Bhave GG, Mathur M. An outbreak of meningitis caused by Neisseria meningitidis Group A. J Commun Dis 1989;21:24-6.
43. th edn. Collier L, Balows A, Sussman M, editors. Oxford University Press: New York; 1996. p. 299-318.
44. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp MeJ 1969:129:1307-26.
45. Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989;2:260-3.
46. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001;344:1378-88.
47. Aycock WL, Mueller JH. Meningococcus carrier rates and meningitis incidence. Bacterial Rev 1950;14:115-60.
48. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969;129:1327-48.
49. Gold R. Bacterial meningitis-1982. Am J Med 1983;75:98-101.
50. Grades O, Ewing WH. Antigenic relationship between Escherichia coli and Neisseria meningitidis. J Infect Dis 1970;122:100-3.
51. Vann WF, Liu TY, Robbins JB. Bacillus pumihis polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun 1976;13:1654-62.
52. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991;4:359-95.
53. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention and Control of Meningococcal Disease. MMWR 2000;49:1-10.
54. Stephens DS, Huffman EH, McGee ZA. Interaction of Neisseria meningitidis with human nasopharyngeal mucosa: attachment and entry into columnar epithelial cells. J Infect Dis 1983;148:369-76.
55. Schildkamp RL, Lodder MC, Bijlmer HA, Dankert J, Scholten RJ. Clinical manifestations and course of meningococcal disease in 562 patients. Scand J Infect Dis 1996;28:47-51.
56. Ploysangam T, Sheth AP. Chronic meningococcemia in childhood: case report and review of the literature. Pediatr Dermatol 1996;13:483-7.
57. Wells M, Gibbons RB. Primary meningococcal arthritis:case report and review of the literature. Mil Med 1997;162:769-72.
58. Blaser MJ, Reingold AL, Alsever RN, Hightower A. Primary meningococcal pericarditis: a disease of adults associated with serogroup C Neisseria meningitidis. Rev Infect Dis 1984:6:625-32.
59. Ødegaard A. Unusual manifestations of meningococcal infection. A review. NIPH Ann. 1983;6:59-63.
60. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995;123:937-40.
61. Caugant DA, Høiby EA, Frøholm EO, Brandtzaeg P. Polymerase chain reaction for case ascertainment of meningococcal meningitis:application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis 1996;28:149-53.
62. van Deuren M, van Dijke BJ, Koopman RJ, Horrevorts AM, Meis JF, Santman FW, et al. Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions. BMJ 1993;306:1229-32.
63. Laboratory Methods for the Diagnosis of Meningitis Caused by Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. Centers for Disease Control and Prevention 1998.
64. nd ed. World Health Organisation. WHO/EMC/BAC/ 98.3. World Health Organization: Geneva; 1998. p. 1-84.
65. Dunbar SA, Eason RA, Musher DM, Clarridge JE. Microscopic examination and broth culture of cerebrospinal fluid in diagnosis of meningitis. J Clin Microbiol 1998;36:1617-20.
66. th edn. Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, editors. ASM Press: Washington DC; 1997. p. 473-83.
67. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing M100-S15. Clinical and Laboratory Standard Institute: Wayne, Pennsylvania; 2005.
68. Hughes JH, Biedenbach DJ, Erwin ME, Jones RN. E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates. J Clin Microbiol 1993;31:3255-9.
69. Richardson DC, Louie L, Louie M, Simor AE. Evaluation of a rapid PCR assay for diagnosis of meningococcal meningitis. J Clin Microbiol 2003;41:3851-3.
70. Jordens JZ, Heckels JE. A novel porA-based real-time PCR for detection of meningococcal carriage. J Med Microbiol 2005;54:463-6.
71. Fernandez-Rodriguez A, Vazquez JA, Suarez-Mier MP, Aguilera B, Ballesteros S, De la Fuente L, et al. Latex agglutination for bacterial antigens and meningococcus PCR: two useful tools in legal sudden deaths. Forensic Sci Int 2005;147:13-20.
72. de Filippis I, do Nascimento CR, Clementino MB, Sereno AB, Rebelo C, Souza NN, et al. Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene. Diagn Microbiol Infect Dis 2005;51:85-90.
73. Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 2004;42:320-8.
74. Tzanakaki G, Tsopanomichalou M, Kesanopoulos K, Matzourani R, Sioumala M, Tabaki A, et al. Simultaneous single-tube PCR assay for the detection of Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae. Clin Microbiol Infect 2005;11:386-90.
75. Healy M, Huong J, Bittner T, Lising M, Frye S, Raza S, et al. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol 2005;43:199-207.
76. th edn Murry PR, Barron EJ, Pfaller MA, Jorgensen JH, Yolken RH, editors. ASM Press: Washington DC; 2003. p. 585-608.
77. Ecker DJ, Sampath R, Blyn LB, Eshoo MW, Ivy C, Ecker JA, et al. Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance. Proc Natl Acad Sci U S A 2005;102:8012-7.
78. Schwentker FF, Gelman S, Long PH. The treatment of meningococcal meningitis with sulfanilamide. Preliminary report. JAMA 1937;108:1407-8.
79. Dillon JR, Pauze M, Yeung KH. Spread of penicillinase-producing and transfer plasmids from the gonococcus to Neisseria meningitidis. Lancet 1983;1:779-81.
80. Galimand M, Gerbaud G, Guibourdenche M, Riou JY, Courvalin P. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998;339:868-74.
81. Shultz TR, Tapsall JW, White PA, Newton PJ. An Invasive Isolate of Neisseria meningitidis Showing Decreased Susceptibility to Quinolones. Antimicrob. Agents Chemother 2000;44:1116.
82. Winterscheid KK, Whittington WL, Roberts MC, Schwebke JR, Holmes KK. Decreased susceptibility to penicillin G and Tet M plasmids in genital and anorectal isolates of Neisseria meningitidis. Antimicrob Agents Chemother 1994;38:1661-3.
83. Sarkar R, Sharma S, Natarajan R, Agarwal DS. Sulphadiazine resistant group 'A' meningococci isolated during the meningitis outbreak in Delhi (1985). Indian J Med Res 1987;85:612-6.
84. Kumar R, Khurana S, Gupta BK. Meningococcal meningitis in Ludhiana. Indian J Pathol Microbiol. 1992;35:340-4.
85. Pecoul B, Varaine F, Keita M, Soga G, Djibo A, Soula G, et al. Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet 1991;338:862-6.
86. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1997;46:13-21.
87. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.:CD001093.pub2. DOI:10.1002/14651858.CD001093.pub2.
88. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotschlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979;140:690-7.
89. Rosenstein N, Levine O, Taylor JP, Evans D, Plikaytis BD, Wenger JD, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998;279:435-9.
90. Veeken H, Ritmeijer K, Hausman B. Priority during a meningitis epidemic: vaccination or treatment? Bull WHO 1998;76:135-41.
91. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 1988;260:2686-9.
92. Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986;154:1033-6.
93. Scheifele DW, Fjornson G, Boraston S. Local adverse effects of meningococcal vaccine. Can Med Assoc J 1994;150:14-5.
94. Ceesay SJ, Allen SJ, Menon A, Todd JE, Cham K, Carlone GM, et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993;167:1212-6.
95. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7.
96. Griffiss JM, Yamasaki R, Estabrook M, Kim JJ. Meningococcal molecular mimicry and the search for an ideal vaccine. Trans R Soc Trop Med Hyg 1991;85:S32-6.
97. Ramsay ME Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001 ;357:195-6.
98. Healy CM, Baker CJ. The future of meningococcal vaccines. Pediatr Infect Dis J 2005;24:175-6.
99. Jennings HJ. JV-propionylated group B meningococcal polysaccharide glycoconjugate vaccine against group B meningococcal meningitis. Int J Infect Dis 1997;1:158-64.
100. Frasch CE. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev 1989;2:S134-8.
101. Diaz Romero J, Outschoorn IM. Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clin Microbiol Rev 1994;7:559-75.
102. Haneberg B, Dalseg R, Wedege E, Hoiby EA, Haugen IE, Oftung F, et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistant local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998;66:1334-41.